New Data Shows Intercept's Fixed Dose Obeticholic Acid Combo Normalize Multiple Biomarkers In Liver Disease
Portfolio Pulse from Vandana Singh
Intercept Pharmaceuticals announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213, showing the therapeutic potential of the combination of obeticholic acid (OCA) and bezafibrate in primary biliary cholangitis (PBC). Over half of the patients receiving OCA5-10/B400 achieved normal range alkaline phosphatase (ALP) at four weeks with continued improvement through week 12. ICPT shares are up 6.81% at $12.08.
June 07, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intercept Pharmaceuticals' ongoing Phase 2 study shows promising results for OCA and bezafibrate combo in PBC treatment, leading to a 6.81% increase in ICPT shares.
The positive initial results from Intercept Pharmaceuticals' ongoing Phase 2 study indicate the potential of the OCA and bezafibrate combination in treating primary biliary cholangitis. This news has a direct impact on ICPT's stock price, as it demonstrates the company's progress in developing effective treatments. The 6.81% increase in ICPT shares reflects the market's positive reaction to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100